ABTB1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the HeLa human cervical adenocarcinoma cell line, engineered to disrupt the ABTB1 gene. This product provides a heterogeneous loss-of-function model for studying ABTB1-dependent ubiquitination and signaling. The gene disruption eliminates wild-type ABTB1 expression, enabling investigation of its role in PTEN degradation and oncogenic pathways.
The host HeLa cell line is an HPV-18-positive, p53-inactivated cervical adenocarcinoma model with epithelial-like morphology, widely used to study growth factor signaling and tumor suppressor networks. The combination of p53 loss and HPV oncoprotein expression enhances the impact of ABTB1-mediated PTEN degradation, creating a permissive environment for evaluating the ABTB1-PI3K axis. HeLa cells?? robust characteristics support consistent biochemical and phenotypic assays for the ubiquitin-proteasome system.
ABTB1 acts as a substrate-specific adaptor for the Cullin-3?CRBX1 E3 ubiquitin ligase, selectively binding PTEN and catalyzing its polyubiquitination and proteasomal degradation. PTEN loss removes inhibition of PI3K signaling, leading to PIP3 accumulation and Akt phosphorylation at Thr308 and Ser473. Akt then phosphorylates TSC2, activating mTORC1 and promoting protein synthesis. Upstream regulators include EGF receptor signaling and hypoxia, which modulate ABTB1 expression and PTEN stability. Co-immunoprecipitation, ubiquitination assays, and phospho-Akt Western blotting are key readouts in this system.
In HPV-18-positive HeLa cells, ABTB1 knockout allows dissection of PTEN degradation??s contribution to PI3K/Akt-driven malignancy. The p53-deficient background likely increases reliance on PTEN to restrain PI3K signaling. Knocking out ABTB1 is predicted to stabilize PTEN, reduce Akt phosphorylation, and suppress mTORC1 activity, enabling functional tests of ABTB1 in proliferation and migration. The epithelial morphology supports wound healing and transwell invasion assays, while the knockout facilitates drug sensitivity screens for PI3K/Akt/mTOR inhibitors.
Researchers can use these cells to study PTEN ubiquitination via immunoprecipitation and ubiquitination assays, and monitor Akt/mTORC1 signaling by phospho-Akt and phospho-S6 Western blotting. Functional assessments include MTT proliferation, scratch wound migration, and Matrigel invasion assays. The polyclonal population reduces clonal artifacts and is suitable for RNA-seq transcriptomics and drug sensitivity profiling with PI3K, Akt, or mTOR inhibitors. This product serves mechanism-driven investigations of ABTB1 in PTEN-dependent tumor biology and preclinical therapeutic screening. For details or custom services, contact Ascent Research.
